Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions.
George Athanasios KarpouzasSarah R OrmsethElizabeth HernandezMatthew J BudoffPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Our findings indicate that in RA, biologic DMARD use is associated with reduced CVD risk, protective calcification of noncalcified lesions, and lower likelihood of new plaque formation in patients with early atherosclerosis.
Keyphrases
- cardiovascular events
- coronary artery disease
- rheumatoid arthritis
- disease activity
- cardiovascular disease
- ankylosing spondylitis
- interstitial lung disease
- chronic kidney disease
- signaling pathway
- aortic stenosis
- heart failure
- aortic valve
- systemic sclerosis
- transcatheter aortic valve replacement
- atrial fibrillation